Apalutamide is a non-steroidal selective androgen receptor inhibitor approved for the treatment of high-risk non-metastatic castration-resistant prostate cancer and metastatic hormone-sensitive cancer. The paper describes case patient diagnosed with long-term course disease. was stage 18 years after primary treatment. Systemic apalutamide recommended. Initially, carried out as part extended acc...
